Loading stock data…
Structure Therapeutics Inc. (GPCR)
$51.69+1.98 (+3.98%)
After Hours$52.72+1.03 (+1.99%)· Last close Jun 29
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Structure Therapeutics Inc. in the Healthcare sector is trading at $51.69 with a market capitalization of $2.7B. Wall Street consensus targets $104.59 (16 analysts), implying a +102.3% move over the next 12 months. The stock is currently 46% below its 52-week high of $94.90, remaining 5.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +102.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$89.38M↓ | $13.74M↑ | -$73.79M↓ | -$70.45M↓ | -$56.31M |
| Net Income | -$75.97M↓ | $33.00M↑ | -$65.71M↓ | -$61.66M↓ | -$46.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.77%
Volume
Today's trading volume
700,098
Recent News
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the […]
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, showing up to 16.3% weight loss. With favorable FDA feedback, the company is on track to initiate a Phase 3 registrational trial in Q3 2026. The company […]
Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?
Structure Therapeutics recently reported in Nature Medicine and at the American Diabetes Association’s 86th Scientific Sessions that its oral GLP-1 receptor agonist aleniglipron achieved statistically significant weight loss and improvements in key cardiovascular risk markers in the Phase 2b ACCESS obesity trial, with an acceptable safety and tolerability profile. The company also shared open-label extension data indicating continued weight loss beyond 36 weeks and suggested that patients...
If Viking Therapeutics Is Acquired, Here’s Who Wins
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins